Daniya Malik

Conscious Fund (Conscious) is a venture capital firm founded in 2019 by Michael Hoyos, Henri Sant-Cassia and Richard Skaife. The firm is headquartered in St Paul's Bay, Malta.

ConnectDER, Inc. is a company that aims to accelerate the transition to clean energy by making clean distributed resources the default source of power for the 21st century. The company is based in Falls Church, VA and was founded by Whitman Fulton, who has been the CEO since incorporation. The company offers innovative products that simplify and accelerate the integration of distributed energy resources with the grid. ConnectDER's meter socket adapters are used by the largest electric power utilities and solar installers throughout the country, allowing anyone to connect solar panels or EV chargers to their home at a fraction of the typical time and cost.

Careology Health Ltd. is a British company that provides cancer support through thoughtful technology. The private company is based in London, UK. The company's aim is to simplify the complicated process of dealing with cancer. The company was founded by Paul Elliott Landau and he has been the CEO since incorporation.

Hive Bio Life Sciences Ltd. provides mental healthcare and substance abuse treatment services. The company is based in Leamington Spa, UK. The British company was founded in 2020 by Natalia Vorobyeva and Alex Latyshev. Alex Latyshev has been the CEO since 2020.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.